'Uncategorized' Category
By Simmons Hanly Conroy | May 15, 2012
FDA Label Requirements Fail Consumers Harmed by Generic Defective Drugs
Generic Drug Manufacturers Should Have a Duty to Warn Consumers of New Safety Concerns Generic drugs account for seventy-five percent of filled prescriptions. Buying generic saves money and, often, the drug is… Read More
By Simmons Hanly Conroy | April 10, 2012
FDA Requires Labels of Drospirenone Birth Control, Like Yaz, to Include Increased Blood Clot Risk Warning
The requirements levied against Bayer and its popular birth control Yaz became stricter today. The Food & Drug Administration has issued a safety alert regarding birth control that contains drospirenone, like Yaz and Yasmine,… Read More
By Simmons Hanly Conroy | March 26, 2012
U.S. Regulators Want FDA More Involved with Hip Replacements, Transvaginal Mesh and Other Faulty Medical Devices
Simmons Hanly Conroy is no longer accepting Hip Replacements cases. Bloomberg reports that four Democratic lawmakers, led by Edward Markey of Massachusetts, have issued a bill that would give the FDA the ability… Read More
By Simmons Hanly Conroy | March 19, 2012
Faulty Hip Implants Can Cause Issues Even After Removal
Simmons Hanly Conroy is no longer accepting Hip Replacements cases. A February 2, 2012 article entitled, “Faulty hip implants may cause long-term health, joint damage,” by Janice Lloyd, published on yourlife.usatoday.com, reports… Read More
By Simmons Hanly Conroy | March 6, 2012
Qnexa: Should A Weight Loss Drug with Topamax and Phentermine Get Approval Before Testing? Consumer Reports Weighs In
A ConsumerReports.org article disagrees with experts who recently voted in an overwhelming majority that the Food and Drug Administration should approve the weight loss drug Qnexa and postpone important studies to monitor it for… Read More
By Simmons Hanly Conroy | January 27, 2012
All FDA Committee Members Should Get to Speak Out Regarding Yaz
In a previous blog post, we shared a news story regarding the FDA and the recent Yaz, Yasmin vote that has come under scrutiny. Is the FDA in bed with big pharmaceutical companies?… Read More
By Simmons Hanly Conroy | January 20, 2012
FDA’s Recent Yaz, Yasmin Vote Under Scrutiny
A recent MedPage Today article printed in EveryDay Health* reports that four FDA medical advisors voting on the risks versus benefits of birth control medications, like Yaz and Yasmin, had ties to Bayer. These FDA… Read More
By Simmons Hanly Conroy | January 3, 2012
Vioxx Settlement in Ohio
A November 23, 2011, Cleveland.com article reports that the state of Ohio will receive a $22.8 million settlement from the Merck, the manufacturer of the recalled drug Vioxx. This is according to… Read More
By Simmons Hanly Conroy | November 3, 2011
Yaz Causes More Harm Than Good
The FDA recently released the results of their long-expected study on contraceptives containing drospirenone. It confirmed that women who take contraceptives such as Yaz are 75 percent more likely to suffer serious side effects… Read More
By Simmons Hanly Conroy | October 11, 2011
Avandia Revised Warning Not Adequate, Court Rules
A federal court has agreed with plaintiff’s counsel in a recent ruling that warnings about the dangers of Avandia, a drug used to help manage Type II Diabetes, may have been inadequate, according… Read More
